Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$18,115.81 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRXGet Free Report) Director Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of C$7.45, for a total value of C$18,115.81.

Rostislav Christov Raykov also recently made the following trade(s):

  • On Monday, July 1st, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.13, for a total transaction of C$14,902.03.

Fennec Pharmaceuticals Stock Performance

TSE:FRX opened at C$7.14 on Friday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a market cap of C$195.35 million, a PE ratio of 79.33 and a beta of 0.26. The firm has a 50 day simple moving average of C$8.19 and a 200-day simple moving average of C$10.64. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.00 and a 1-year high of C$15.43.

Fennec Pharmaceuticals (TSE:FRXGet Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The business had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. On average, equities analysts expect that Fennec Pharmaceuticals Inc. will post 0.6058577 EPS for the current year.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Read More

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.